Dr. Tibes is a physician-scientist who sees and treats patients with hematological malignancies as well as heads laboratory research efforts in leukemia research. Further, he is actively conducting early phase (Phase 1/2) clinical trials with novel molecular therapies/agents.
The goal of the translational-clinical research program is to advance care and treatment of patients with hematological malignancies through translational research in leukemia. Research strategies center around identifying novel vulnerabilities and treatment targets in myeloid and lymphoid disorders (AML, MDS, CML, MPNs, ALL) and immediately translate those into new therapy approaches and clinical studies for patients with leukemias. The approach taken is a functional genomics RNA interference (RNAi) approach using siRNA in high-throughput format established by Dr. Tibes for leukemia cells.
With this novel methodology and platform hundreds to thousands of genes can individually be silenced (inhibited) and assessed for their anti-leukemia activity alone or in combination with conventional cytotoxics. Several large-scale RNAi screens were conducted (i.e. with Cytarabine and 5-Azacytidine) and results are being used to design rational clinical combination trials.
Specific research efforts are targeting DNA damage repair and cell cycle checkpoint pathways and finding sensitizers to epigenetic therapies. Parallel biomarker research to identify specific molecular markers to select patients for particular therapies is ongoing.